Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 221

1.

Respiratory complications following mini-invasive laparoscopic and thoracoscopic esophagectomy for esophageal cancer. Experience in 215 patients.

Vrba R, Vrána D, Neoral Č, Melichar B, Aujeský R, Tesarikova J, Cincibuch J, Zapletalová J, Jínek T, Stašek M.

Wideochir Inne Tech Maloinwazyjne. 2019 Jan;14(1):52-59. doi: 10.5114/wiitm.2018.77276. Epub 2018 Jul 24.

2.

Current status of cytoreductive surgery (CRS) and intraperitoneal hyperthermic chemotherapy (HIPEC) in the multimodal treatment of peritoneal surface malignancies.

Klos D, Riško J, Stašek M, Loveček M, Hanuliak J, Skalický P, Lemstrová R, Mohelníková BD, Študentová H, Neoral Č, Melichar B.

Cas Lek Cesk. 2019 Winter;157(8):419-428.

PMID:
30754979
3.

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.

Fuchs CS, Shitara K, Di Bartolomeo M, Lonardi S, Al-Batran SE, Van Cutsem E, Ilson DH, Alsina M, Chau I, Lacy J, Ducreux M, Mendez GA, Alavez AM, Takahari D, Mansoor W, Enzinger PC, Gorbounova V, Wainberg ZA, Hegewisch-Becker S, Ferry D, Lin J, Carlesi R, Das M, Shah MA; RAINFALL Study Group.

Lancet Oncol. 2019 Feb 1. pii: S1470-2045(18)30791-5. doi: 10.1016/S1470-2045(18)30791-5. [Epub ahead of print]

PMID:
30718072
4.

Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial.

Chung HC, Arkenau HT, Lee J, Rha SY, Oh DY, Wyrwicz L, Kang YK, Lee KW, Infante JR, Lee SS, Kemeny M, Keilholz U, Melichar B, Mita A, Plummer R, Smith D, Gelb AB, Xiong H, Hong J, Chand V, Safran H.

J Immunother Cancer. 2019 Feb 4;7(1):30. doi: 10.1186/s40425-019-0508-1.

5.

Tyrosine kinase inhibitors in the first-line treatment for metastatic nonclear cell renal carcinoma: A retrospective analysis of a national database.

Poprach A, Rumanova K, Lakomý R, Chloupková R, Stanik M, Pokrivcak T, Kiss I, Slaby O, Studentova H, Melichar B, Juracek J, Fiala O, Kopecky J, Kopeckova K, Zemanova M, Buchler T.

Urol Oncol. 2019 Jan 22. pii: S1078-1439(18)30511-8. doi: 10.1016/j.urolonc.2018.12.017. [Epub ahead of print]

PMID:
30683455
6.

Genetic analysis of subsequent second primary malignant neoplasms in long-term pancreatic cancer survivors suggests new potential hereditary genetic alterations.

Lovecek M, Janatova M, Skalicky P, Zemanek T, Havlik R, Ehrmann J, Strouhal O, Zemankova P, Lhotova K, Borecka M, Soukupova J, Svebisova H, Soucek P, Hlavac V, Kleibl Z, Neoral C, Melichar B, Mohelnikova-Duchonova B.

Cancer Manag Res. 2019 Jan 10;11:599-609. doi: 10.2147/CMAR.S185352. eCollection 2019.

7.

Jillian Russyll (AKA Jill) Tate.

Plebani M, Gillery P, Jahnke H, Lackner K, Lippi G, Melichar B, Payne DA, Schlattmann P.

Clin Chem Lab Med. 2018 Dec 19;57(2):147. doi: 10.1515/cclm-2018-2394. No abstract available.

PMID:
30645199
8.

Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis.

Buchler T, Chloupkova R, Poprach A, Fiala O, Kiss I, Kopeckova K, Dusek L, Veskrnova V, Slavicek L, Kohoutek M, Finek J, Svoboda M, Petruzelka L, Melichar B.

Cancer Manag Res. 2018 Dec 28;11:359-368. doi: 10.2147/CMAR.S183093. eCollection 2019.

9.

Reversed phase UHPLC/ESI-MS determination of oxylipins in human plasma: a case study of female breast cancer.

Chocholoušková M, Jirásko R, Vrána D, Gatěk J, Melichar B, Holčapek M.

Anal Bioanal Chem. 2019 Feb;411(6):1239-1251. doi: 10.1007/s00216-018-1556-y. Epub 2019 Jan 8.

PMID:
30617406
10.

From Tumor Immunology to Immunotherapy in Gastric and Esophageal Cancer.

Vrána D, Matzenauer M, Neoral Č, Aujeský R, Vrba R, Melichar B, Rušarová N, Bartoušková M, Jankowski J.

Int J Mol Sci. 2018 Dec 20;20(1). pii: E13. doi: 10.3390/ijms20010013. Review.

11.

Biomarkers and pathways of chemoresistance and chemosensitivity for personalized treatment of pancreatic adenocarcinoma.

Zemanek T, Melichar B, Lovecek M, Soucek P, Mohelnikova-Duchonova B.

Pharmacogenomics. 2019 Jan;20(2):113-127. doi: 10.2217/pgs-2018-0073. Epub 2018 Dec 12.

PMID:
30539680
12.

Chronic Inflammation as a Potential Predictive Factor of Nivolumab Therapy in Non-small Cell Lung Cancer.

Svaton M, Zemanova M, Skrickova J, Jakubikova L, Kolek V, Kultan J, Koubkova L, Bejckova A, Salajka F, Hrnciarik M, Melichar B, Vrana D, Konecny M, Chloupkova R, Pesek M.

Anticancer Res. 2018 Dec;38(12):6771-6782. doi: 10.21873/anticanres.13048.

PMID:
30504389
13.

Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies on the Outcome of First-Line Therapy in Metastatic Colorectal Cancer Patients: a Retrospective Registry-Based Analysis.

Fiala O, Veskrnova V, Chloupkova R, Poprach A, Kiss I, Kopeckova K, Dusek L, Slavicek L, Kohoutek M, Finek J, Svoboda M, Petruzelka L, Boubliková L, Dvorak J, Melichar B, Buchler T.

Target Oncol. 2018 Dec;13(6):735-743. doi: 10.1007/s11523-018-0597-7.

PMID:
30353488
14.

HILIC/ESI-MS determination of gangliosides and other polar lipid classes in renal cell carcinoma and surrounding normal tissues.

Hájek R, Lísa M, Khalikova M, Jirásko R, Cífková E, Študent V Jr, Vrána D, Opálka L, Vávrová K, Matzenauer M, Melichar B, Holčapek M.

Anal Bioanal Chem. 2018 Oct;410(25):6585-6594. doi: 10.1007/s00216-018-1263-8. Epub 2018 Jul 28.

PMID:
30054694
15.

Hemodiafiltration and plasma levels of axitinib in a patient with metastatic renal clear cell carcinoma.

Kopecky J, Ticha A, Janeckova H, Bohuslav M.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2018 May 15. doi: 10.5507/bp.2018.021. [Epub ahead of print]

PMID:
29765173
16.

Simulations of centriole of polarized centrosome as a monopole antenna in immune and viral synapses.

Dvorak J, Melichar B, Filipova A, Grimova J, Grimova N, Rozsypalova A, Buka D, Voboril R, Zapletal R, Buchler T, Richter I, Buka D.

J BUON. 2018 Mar-Apr;23(2):514-521.

PMID:
29745101
17.

Lenvatinib for the treatment of kidney cancer.

Študentová H, Vitásková D, Melichar B.

Expert Rev Anticancer Ther. 2018 Jun;18(6):511-518. doi: 10.1080/14737140.2018.1470506. Epub 2018 May 8. Review.

PMID:
29737893
18.

Immunotherapy in mucosal melanoma: a case report and review of the literature.

Studentova H, Kalabova H, Koranda P, Chytilova K, Kucerova L, Melichar B, Vrana D.

Oncotarget. 2018 Apr 3;9(25):17971-17977. doi: 10.18632/oncotarget.24727. eCollection 2018 Apr 3.

19.

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B; CheckMate 214 Investigators.

N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21.

20.

ABC Transporters and Their Role in the Neoadjuvant Treatment of Esophageal Cancer.

Vrana D, Hlavac V, Brynychova V, Vaclavikova R, Neoral C, Vrba J, Aujesky R, Matzenauer M, Melichar B, Soucek P.

Int J Mol Sci. 2018 Mar 15;19(3). pii: E868. doi: 10.3390/ijms19030868. Review.

Supplemental Content

Loading ...
Support Center